JP4718009B2 - 髄膜炎菌由来のｂａｓｂ００６ポリヌクレオチドおよびポリペプチド - Google Patents

髄膜炎菌由来のｂａｓｂ００６ポリヌクレオチドおよびポリペプチド Download PDF

Info

Publication number
JP4718009B2
JP4718009B2 JP2000546017A JP2000546017A JP4718009B2 JP 4718009 B2 JP4718009 B2 JP 4718009B2 JP 2000546017 A JP2000546017 A JP 2000546017A JP 2000546017 A JP2000546017 A JP 2000546017A JP 4718009 B2 JP4718009 B2 JP 4718009B2
Authority
JP
Japan
Prior art keywords
polypeptide
seq
polynucleotide
sequence
basb006
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000546017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002512800A (ja
JP2002512800A5 (enExample
Inventor
ソナード，ジョエル
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2002512800A publication Critical patent/JP2002512800A/ja
Publication of JP2002512800A5 publication Critical patent/JP2002512800A5/ja
Application granted granted Critical
Publication of JP4718009B2 publication Critical patent/JP4718009B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
JP2000546017A 1998-04-24 1999-04-20 髄膜炎菌由来のｂａｓｂ００６ポリヌクレオチドおよびポリペプチド Expired - Fee Related JP4718009B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9808866.9 1998-04-24
GBGB9808866.9A GB9808866D0 (en) 1998-04-24 1998-04-24 Novel compounds
PCT/EP1999/002766 WO1999055873A2 (en) 1998-04-24 1999-04-20 Basb006 polynucleotide(s) and polypeptides from neisseria meningitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010044312A Division JP2010166920A (ja) 1998-04-24 2010-03-01 髄膜炎菌由来のｂａｓｂ００６ポリヌクレオチドおよびポリペプチド

Publications (3)

Publication Number Publication Date
JP2002512800A JP2002512800A (ja) 2002-05-08
JP2002512800A5 JP2002512800A5 (enExample) 2006-04-27
JP4718009B2 true JP4718009B2 (ja) 2011-07-06

Family

ID=10830985

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000546017A Expired - Fee Related JP4718009B2 (ja) 1998-04-24 1999-04-20 髄膜炎菌由来のｂａｓｂ００６ポリヌクレオチドおよびポリペプチド
JP2010044312A Pending JP2010166920A (ja) 1998-04-24 2010-03-01 髄膜炎菌由来のｂａｓｂ００６ポリヌクレオチドおよびポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010044312A Pending JP2010166920A (ja) 1998-04-24 2010-03-01 髄膜炎菌由来のｂａｓｂ００６ポリヌクレオチドおよびポリペプチド

Country Status (8)

Country Link
US (3) US6696062B1 (enExample)
EP (2) EP2360260A1 (enExample)
JP (2) JP4718009B2 (enExample)
CN (1) CN1203180C (enExample)
AU (1) AU3928499A (enExample)
CA (1) CA2326375A1 (enExample)
GB (1) GB9808866D0 (enExample)
WO (1) WO1999055873A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4472866B2 (ja) * 1997-11-06 2010-06-02 カイロン ソチエタ ア レスポンサビリタ リミタータ ナイセリア抗原
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
NZ515935A (en) 1999-05-19 2004-01-30 Chiron S Combination Neisserial compositions and vaccines for the prevention of infections due to Neisseria bacteria such as meningococcal meningitis
EP2275553B1 (en) 1999-10-29 2015-05-13 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigenic peptides
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
JP4763210B2 (ja) * 2000-02-28 2011-08-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ナイセリアのタンパク質の異種発現
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US20050232936A1 (en) 2001-07-27 2005-10-20 Chiron Corporation Meningococcus adhesins nada, app and orf 40
RU2317106C2 (ru) * 2002-08-02 2008-02-20 ГлаксоСмитКлайн Байолоджикалз с.а. Нейссериальные вакцинные композиции, содержащие комбинацию антигенов
CA2489030A1 (en) * 2002-08-02 2004-02-19 Glaxosmithkline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
MXPA05003863A (es) 2002-10-11 2005-09-08 Chiron Srl Vacunas polipeptidicas para amplia proteccion contra lineas hipervirulentas de meningococos.
CA2539715C (en) 2003-10-02 2015-02-24 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US9387239B2 (en) 2008-05-30 2016-07-12 U.S. Army Medical Research And Materiel Command Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
WO2011110634A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Vaccine composition
US9365624B2 (en) 2010-03-11 2016-06-14 Glaxosmithkline Biologicals, S.A. Vaccine

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
RU2023448C1 (ru) * 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB9022190D0 (en) 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
FR2682041B1 (fr) * 1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins Vaccin contre les infections a neisseria meningitidis.
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
DK0689454T4 (da) 1993-03-23 2005-05-30 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryl-lipid A
US5747292A (en) 1993-04-06 1998-05-05 Fred Hutchinson Cancer Research Center Chimeric cytokine receptors in lymphocytes
WO1994029458A1 (en) 1993-06-07 1994-12-22 Amgen Inc. Hybrid receptor molecules
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
US6245337B1 (en) * 1994-08-25 2001-06-12 Washington University Haemophilus adherence and penetration proteins
US6121037A (en) * 1994-10-18 2000-09-19 Stojiljkovic; Igor Bacterial hemoglobin receptor genes
US6265567B1 (en) * 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
AU5552396A (en) 1995-04-21 1996-11-07 Human Genome Sciences, Inc. Nucleotide sequence of the haemophilus influenzae rd genome, fragments thereof, and uses thereof
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
ATE208629T1 (de) * 1996-08-27 2001-11-15 Chiron Corp Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
JP4472866B2 (ja) * 1997-11-06 2010-06-02 カイロン ソチエタ ア レスポンサビリタ リミタータ ナイセリア抗原
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
GB9808734D0 (en) * 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
EP2270169A3 (en) * 1999-03-12 2011-06-15 GlaxoSmithKline Biologicals SA Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
GB0025171D0 (en) * 2000-10-13 2000-11-29 Smithkline Beecham Biolog Novel compounds
US20050232936A1 (en) * 2001-07-27 2005-10-20 Chiron Corporation Meningococcus adhesins nada, app and orf 40

Also Published As

Publication number Publication date
GB9808866D0 (en) 1998-06-24
AU3928499A (en) 1999-11-16
CA2326375A1 (en) 1999-11-04
CN1336957A (zh) 2002-02-20
EP1071783A2 (en) 2001-01-31
US20100196409A1 (en) 2010-08-05
JP2002512800A (ja) 2002-05-08
US7419824B2 (en) 2008-09-02
EP2360260A1 (en) 2011-08-24
WO1999055873A3 (en) 2000-03-09
US20040137530A1 (en) 2004-07-15
US6696062B1 (en) 2004-02-24
WO1999055873A2 (en) 1999-11-04
JP2010166920A (ja) 2010-08-05
CN1203180C (zh) 2005-05-25

Similar Documents

Publication Publication Date Title
JP2010166920A (ja) 髄膜炎菌由来のｂａｓｂ００６ポリヌクレオチドおよびポリペプチド
JP2010166921A (ja) 髄膜炎菌由来のｂａｓｂ０２９ポリヌクレオチドおよびポリペプチド
US20040132983A1 (en) BASB013 DNA and proteins from neisseria meningitidis
EP1080198B1 (en) Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
EP1112366B1 (en) Polynucleotides and polypeptides basb033 from neisseria meningitidis and their uses
HK1160490A (en) Basb006 polynucleotide(s) and polypeptides from neisseria meningitis
HK1091861A (en) Basb029 polynucleotide(s) and polypeptides from neisseria meningitis
HK1036300B (en) Basb029 polynucleotides and polypeptides from neisseria meningitis
HK1038041B (en) Polynucleotides and polypeptides basb033 from neisseria meningitidis and their uses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090122

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101104

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101111

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110331

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140408

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees